

Table 4.26

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2010-2014
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	76,695	99.9%	58,604	99.9%	8,733	99.9%	7,985	99.9%	290	100.0%	7,939	99.9%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^e	65,234	85.0%	49,267	84.0%	7,664	87.6%	7,232	90.5%	253	87.2%	6,798	85.5%
Cribriform carcinoma <i>in situ</i> (8201/2)	6,769	8.8%	5,030	8.6%	814	9.3%	816	10.2%	18	6.2%	696	8.8%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	5,417	7.1%	4,226	7.2%	541	6.2%	578	7.2%	20	6.9%	481	6.1%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	21,448	27.9%	16,542	28.2%	2,436	27.9%	2,050	25.7%	97	33.4%	2,204	27.7%
Comedocarcinoma <i>in situ</i> (8501/2)	6,419	8.4%	4,849	8.3%	706	8.1%	773	9.7%	35	12.1%	629	7.9%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,148	1.5%	780	1.3%	204	2.3%	141	1.8%	-	-	120	1.5%
Noninfiltrating intracystic carcinoma(8504/2)	249	0.3%	160	0.3%	36	0.4%	52	0.7%	-	-	29	0.4%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,205	1.6%	950	1.6%	153	1.7%	86	1.1%	-	-	138	1.7%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	22,396	29.2%	16,602	28.3%	2,764	31.6%	2,692	33.7%	76	26.2%	2,486	31.3%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	8,904	11.6%	7,339	12.5%	783	9.0%	515	6.4%	32	11.0%	905	11.4%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	8,886	11.6%	7,327	12.5%	778	8.9%	515	6.4%	31	10.7%	904	11.4%
Lobular CIS ^f with other CIS ^f (8524/2)	18	0.0%	-	-	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,043	2.7%	1,626	2.8%	222	2.5%	169	2.1%	-	-	180	2.3%
Other adenocarcinomas ^g	506	0.7%	368	0.6%	63	0.7%	66	0.8%	-	-	56	0.7%
Other <i>in situ</i> histologies ^h	85	0.1%	62	0.1%	-	-	-	-	-	-	-	-
Total	76,780	100.0%	58,666	100.0%	8,746	100.0%	7,990	100.0%	290	100.0%	7,948	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^g CIS = Carcinoma *in situ*.

^h Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

ⁱ Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.